Fund Information / Factsheet • Feb 23, 2024
Fund Information / Factsheet
Open in ViewerOpens in native device viewer

declared but not yet paid.
Please note that this chart could include dividends that have been
contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance does not predict future returns.
market and currency fluctuations, and you may not get back the amount originally invested. Please refer to the glossary for the definition of share price total return.
How to invest Go to www.janushenderson.com/howtoinvest Find out more Go to www.hendersoneuropeanfocus.com
The Company seeks to maximise total return (a combination of income and capital growth) from a portfolio of stocks listed in Europe.
A focused investment trust of between 35 and 45 companies in Europe with an emphasis on maximising total return.
| NAV (cum income) | 192.3p |
|---|---|
| NAV (ex income) | 191.8p |
| Share price | 171.0p |
| Discount(-)/premium(+) | -11.1% |
| Yield | 2.8% |
| Net gearing | - |
| Net cash | - |
| Total assets Net assets |
£439m £409m |
| Market capitalisation | £364m |
| Total voting rights | 212,768,122 |
| Total number of holdings | 40 |
| Ongoing charges (year end 30 Sep 2023) |
0.80% |
| Benchmark | FTSE World Europe (Ex UK) Index |
| Overall Morningstar RatingTM As of 31/01/2024 |
|
| Morningstar Medalist RatingTM Effective 16/10/2023 |
|
| Analyst-Driven %: 100.00 Data Coverage %: 100.00 |
|
| Source: BNP Paribas for holdings information and Morningstar for |
all other data. Differences in calculation may occur due to the methodology used.
Please note that the total voting rights in the Company do not include shares held in Treasury.
| Top 10 holdings | (%) | |
|---|---|---|
| Novo Nordisk | 5.8 | |
| ASML | 5.3 | |
| UPM-Kymmene | 5.3 | |
| TotalEnergies | 3.9 | |
| Safran | 3.9 | |
| LVMH Moet Hennessy Louis Vuitton | 3.8 | |
| Airbus | 3.8 | |
| Schneider Electric | 3.6 | |
| SAP | 3.6 | |
| Siemens | 3.1 |


The above sector breakdown may not add up to 100% due to rounding.
References made to individual securities do not constitute a n/a n/a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.
The above geographical breakdown may not add up to 100% as this only shows the top 10.


10 year total return of £1,000
Please remember that past performance does not predict future returns. The value of an investment and the income from it can rise as well as fall as a result of market and currency fluctuations, and you may not get back the amount originally invested. Please refer to the glossary for the definition of share price total return.
| Stock code | HEFT |
|---|---|
| AIC sector | AIC Europe |
| Benchmark | FTSE World Europe (Ex UK) Index |
| Company type | Conventional (Ords) |
| Launch date | 1947 |
| Financial year | 30-Sep |
| Dividend payment | June, February |
| Risk rating (Source: Numis) |
Slightly above average |
| Management fee | 0.65% for net assets up to £300m. 0.55% for net assets above £300m. |
| Performance fee | No |
| (See Annual Report & Key Information Document for more information) | |
| Regional focus | Europe |
| Fund manager appointment |
Tom O'Hara 2020 John Bennett 2010 |


How to invest Go to www.janushenderson.com/howtoinvest Customer services 0800 832 832

Factsheet - at 31 January 2024 Marketing Communication
It was a typically contrarian start to the new year, following the euphoric end to 2023.
European equity markets declined during the first half of January, while a sector rotation punished the prior year's winners (technology stocks) and rewarded the laggards (big pharmaceutical firms).
Europe's largest (and generally 'quality' and 'high growth') companies across technology, health care and luxury resumed leadership from mid-January, thanks to strong fourth quarter results. This pushed the benchmark to finish the month up around 1%.
Top positive contributors were ASML (semiconductor capital equipment), SAP (business software), Safran (aerospace) and Novo Nordisk (diabetes and obesity treatments). The common denominator here is that they are all European companies with global leadership in their respective fields, which augments the leadership by large-cap stocks in equity markets. This corresponds to a theme - which we refer to as 'big is beautiful' - that we expect to persist in an era of non-zero inflation and nonzero interest rates. We think the real economy implications are such that large incumbents are likely to become more powerful.
The biggest detractors included Syensqo (the specialty chemicals successor of the newly-separated Solvay), which was likely seeing some shareholder register rotation, and Infineon, as the market continued to worry about the cyclical downside in the semiconductor industry. The Company's energy positions also continued to underperform despite rising geopolitical tensions which, in addition to the resilient global economy, should typically push fossil fuel prices upwards.
In terms of activity, we opened a position in Finnish elevator company Kone, as we believe the impact on the profit and loss (P&L) from further China property market weakness is now manageable, while the highly defensive 'services' side of the business (maintaining elevators under long-term contracts) continued to demonstrate profitable growth. We exited the positions in Grifols and Sandvik - the latter in order to fund the purchase of Kone as described above, where we have higher conviction.
We continue to believe in the likelihood of higher inflation and higher interest rates in the years ahead, at least relative to the decade prior to the Covid pandemic. This is not to argue against the potential for near-term disinflation of a more cyclical nature, as supply shocks from both Covid and the Ukraine war are lapsed.
That said, even given the shifting rhetoric from central
banks, we continue to lean much more towards a central bank 'plateau' rather than a 'pivot' on interest rates. This is, unless we witness a sharp economic contraction. However, given the fiscal bazooka being deployed under 'Bidenomics' and the need for Europe to follow suit, we may not see the economic 'hard landing' (recession) the market intermittently panics over, even if consumers do moderate their appetite to spend.
Longer term, we expect a clear shift towards a multipolar world, of which deglobalisation – and the capital intensive likes of 'Bidenomics' – is an outcome. We could also see a political shift in favour of populist/pro-labour policies, from both traditional 'left' and 'right' ends of the political spectrum. This could mean stronger wage inflation and greater labour market friction. It also leads us to believe equity investors will need to be more sensitive to valuation when making stock purchasing decisions.
The real economy implications will also present opportunities for stock-pickers. Enablers of deglobalisation (think industrial automation, digitalisation, electrification and construction materials firms) could thrive, while large incumbents across many industries (such as brewing, food catering and enterprise software) could see their already dominant positions enhanced as the end of virtually 'free' money tempers the threat of disruption by unprofitable start-ups. Europe offers plentiful opportunities to access these themes, being home to large global champions at what we see as reasonable valuations.
Factsheet - at 31 January 2024 Marketing Communication
The amount by which the price per share of an investment company is either lower (at a discount) or higher (at a premium) than the net asset value per share (cum income), expressed as a percentage of the net asset value per share.
The effect of borrowing money for investment purposes (financial gearing). The amount a company can "gear" is the amount it can borrow in order to invest. Gearing is used in the expectation that the returns on the investments bought will exceed the costs of the borrowings that funded the purchase. This Company can also use synthetic gearing through derivatives and foreign exchange hedging and/or other non-fully funded instruments or techniques.
The Company's leverage is the sum of financial gearing and synthetic gearing. Details of the Company's leverage limits can be found in both the Key Information Document and Annual Report. Where a company utilises leverage, the profits and losses incurred by the company can be greater than those of a company that does not use leverage.
Share price multiplied by the number of shares in issue, excluding treasury shares, at month end. Shares typically priced mid-market at month-end closing.
The total value of a Company's assets less its liabilities.
The value of investments and cash, including current year revenue, less liabilities (prior charges such as loans, debenture stock and preference shares at fair value).
The value of investments and cash, excluding current year revenue, less liabilities (prior charges such as loans, debenture stock and preference shares at fair value).
The theoretical total return on shareholders' funds per share reflecting the change in Net Asset Value (NAV) assuming that dividends paid to shareholders were reinvested at NAV at the time the shares were quoted ex-dividend. A way of measuring investment management performance of investment trusts which is not affected by movements in discounts/premiums.
Total assets minus any liabilities such as bank loans or creditors.
A company's net exposure to cash/cash equivalents expressed as a percentage of shareholders' funds, after any offset against its gearing. This is only shown for companies that have gearing in place.
A company's total assets (less cash/cash equivalents) divided by shareholders' funds expressed as a percentage.
The total expenses for the financial year (excluding performance fee), divided by the average daily net assets, multiplied by 100.
The key measure used to assess risk is volatility of returns, using historic net asset value (NAV) performance of the Company over 1 and 3 years. In this instance volatility measures how much a company's NAV fluctuates over time in relation to the UK Equity market. The higher a volatility figure, the more the NAV has fluctuated (both up and down) over time. Please note that risk categorisations are indicative and based principally on historic data and should not be solely relied upon when making investment decisions.
Closing mid-market share price at month end.
The theoretical total return to the investor assuming that all dividends received were reinvested in the shares of the company at the time the shares were quoted ex-dividend. Transaction costs are not taken into account.
Cum Income NAV multiplied by the number of shares, plus prior charges at fair value.
Calculated by dividing the current financial year's dividends per share (this will include prospective dividends) by the current price per share, then multiplying by 100 to arrive at a percentage figure.
For a full list of terms please visit: https://www.janushenderson.com/engb/investor/glossary/
Factsheet - at 31 January 2024 Marketing Communication

Overall Morningstar Rating™ is a measure of a fund's risk-adjusted return, relative to similar funds. Fund share classes are rated from 1 to 5 stars, with the best performers receiving 5 stars and the worst performers receiving a single star.
Overall Morningstar Rating™ is shown for an investment company achieving a rating of 4 or 5.
Morningstar Medalist Rating™
Ratings should not be taken as a recommendation. For more detailed information about Morningstar Ratings, including its methodology, please go to www.global.morningstar.com/managerdisclosures.
Not for onward distribution. Before investing in an investment trust referred to in this document, you should satisfy yourself as to its suitability and the risks involved, you may wish to consult a financial adviser. This is a marketing communication. Please refer to the AIFMD Disclosure document and Annual Report of the AIF before making any final investment decisions. Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. Tax assumptions and reliefs depend upon an investor's particular circumstances and may change if those circumstances or the law change. Nothing in this document is intended to or should be construed as advice. This document is not a recommendation to sell or purchase any investment. It does not form part of any contract for the sale or purchase of any investment. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.
Issued in the UK by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Henderson Investors International Limited (reg no. 3594615), Janus Henderson Investors UK Limited (reg. no. 906355), Janus Henderson Fund Management UK Limited (reg. no. 2678531), (each registered in England and Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial Conduct Authority) and Janus Henderson Investors Europe S.A. (reg no. B22848 at 2 Rue de Bitbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier).
Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.